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The present study aimed to characterize systematically the target epitopes of T cell responses in CBV4 structural proteins.
These were studied by synthesizing 86 overlapping 20-aa-long peptides covering the known sequence of CBV4 structural
proteins and analyzing the proliferation responses of 18 CBV4-specific T cell lines against these peptides. Recognized
peptides differed depending on the HLA-DR genotype of the T cell donor. They were concentrated to the VP4 and VP2 regions
as six of seven common peptide epitopes located in this region, whereas there was only one in the VP3 region and none in
the VP1 region. Peptides from conserved areas were recognized more often (on average, 15% of them stimulated each T cell
line) than those derived from variable areas (3%) (P  0.0001, Fisher’s exact test). Some conserved peptides inducing T cell
responsiveness in most subjects were identified, a knowledge which can be useful in the development of new synthetic
vaccines. © 2002 Elsevier Science (USA)INTRODUCTION
Enteroviruses are small, nonenveloped RNA viruses
belonging to the family of Picornaviridae. The enterovirus
genome is a single, positive-strand RNA molecule of
about 7500 nt. The P1 region codes for the four structural
proteins, which form the virus capsid: the major capsid
proteins VP1–3 are on the virion surface, while VP4 is
internal. VP4 and VP2 are synthesized as a precursor
protein VP0, which undergoes a maturation cleavage late
in the capsid assembly. The P2 and P3 regions encode
seven nonstructural proteins 2A, 2B, 2C, 3A, 3B, 3C, and
3D, which are responsible for functions needed in repli-
cation (Rueckert, 1996). Comparison of enterovirus ge-
nomes in the capsid-coding region has indicated the
presence of four genetic clusters among human entero-
viruses. Cluster A contains 11 coxsackievirus A sero-
types (CAVs) and enterovirus 71. Cluster B contains all
coxsackievirus B serotypes (CBVs), CAV9 serotype, and
echoviruses; cluster C contains polioviruses and 11 CAV
serotypes, and cluster D contains enteroviruses 68 and
70 (Hyypia¨ et al., 1997; Oberste et al., 1999; Po¨yry et al.,
1996). Highest similarity between enterovirus strains is
1 To whom correspondence and reprint requests should be ad-
dressed at Department of Virology, University of Turku, Kiinamyllynkatu217seen within the clusters and for example within cluster B
the serotypes share at least 96% of amino acid (aa) in
their VP4 protein. Most variable is the VP1 protein (at
least 78% similarity) and VP2 and VP3, sharing at least 85
and 83% of aa, respectively. The nonstructural proteins
show considerably less variation than structural proteins
(Po¨yry et al., 1996).
Enteroviruses are common human pathogens. Most
infections are subclinical or accompanied by mild com-
mon cold-type symptoms, but several distinct complica-
tions occur, such as meningitis, myocarditis, and sepsis-
like infections in newborns (Melnick, 1996). Increasing
evidence also implicates enteroviruses among environ-
mental triggers in the pathogenesis of type 1 diabetes
(Hyo¨ty et al., 1998). Immunity against enterovirus infec-
tions is created by the presence of neutralizing antibod-
ies, which by definition are serotype specific. Localiza-
tion of neutralizing antigenic sites of polioviruses has
been well characterized by using antigenic variants and
monoclonal antibodies. The major neutralizing antigenic
sites are located in the VP1 protein and, to a lesser
extent, in the VP2 and VP3 polypeptides (Hogle et al.,
1985; Mateu, 1995; Minor et al., 1986). The significance of
cell-mediated immunity in enterovirus infections has not
been extensively analyzed but it may be involved in the
development of disease-associated complications (BeckKey Words: coxsackievirus B4 (CBV4); enterovirus;
cross-reactivity.
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0042-6822/02 $35.00
© 2002 Elsevier Science (USA)
All rights reserved.T cell
on
as enterovirus antigens have been recognized by T cells
established from donor without neutralizing antibodies to
the tested enterovirus serotype (Beck and Tracy, 1990;
Cello et al., 1996) and T cell lines specific to different
enteroviruses have also been recognizing widely other
enterovirus antigens (Graham et al., 1993).
In this study we systematically mapped T cell epitopes
from CBV4 structural proteins. This was made by ana-
lyzing the responsiveness of 18 CBV4-specific T cell
lines against a panel of eighty-six 20-aa-long synthetic
peptides covering the sequence of CBV4 structural pro-
teins. We demonstrated that the exact peptide epitopes
recognized by T cells were defined by the HLA genotype
of the donor and were able show that these epitopes
were concentrated to the conserved areas of the struc-
tural proteins.
RESULTS
CBV4-specific T cell response to synthetic peptides
and in vitro produced proteins
Eighteen coxsackievirus B4 (CBV4)-specific T cell
lines were established from 18 donors and their re-
sponses to 86 synthetic peptides were analyzed. These
20-aa-long peptides overlapped with each other by 10 aa
and covered the whole sequence of the CBV4 structural
proteins VP1, VP2, VP3, and VP4. In the first phase the
epitopes were mapped by using 17 pools of five to six
peptides and dissecting the responses by including sin-
gle peptides of stimulating pools in the second test (Fig.
1). Recognized peptides differed markedly between sub-
jects and depended on the HLA genotype of the donor
(Table 1). T cell lines established from each donor rec-
ognized up to 15 different peptides from CBV4 structural
proteins. Nine T cell lines of 15 were stimulated by
CBV3-VP1 protein and six of them also recognized syn-
thetic peptide(s) and/or peptide pool(s) from VP1 region.
The other six T cell lines, which did not respond to
CBV3-VP1 protein, did not respond to any of the synthetic
peptides covering the CBV4 VP1 sequence (P  0.028,
Fisher’s exact test). All 17 tested T cell lines had re-
sponse to CBV4-VP0 protein and also recognized pep-
tides covering the sequence of VP0 (including VP4 and
VP2 proteins).
Phenotype of the CBV4-specific T cell lines
The CBV4-specific T cell lines contained mixed phe-
notype of CD4 and CD8 T cells. An average of 42% of
all CD3 T cells contained the CD4 molecule and 27%
contained the CD8 molecule when the phenotype of the
CBV4-specific T cell lines was analyzed by flow cytom-
etry (Facscan, Becton–Dickinson) using FITC- or phyco-
erythrin-conjugated mAb (Coulter) to the CD4 and CD8 T
cell surface markers. After depletion of CD8-positive T
cells, one randomly selected CBV4-specific T cell line
was further cultured and the pattern of recognized pep-
tides was analyzed. This new T cell line contained only
1% CD8 T cells and recognized all the same peptides
as the original one (containing 10% CD8 T cells) (data
not shown).
Effects of HLA genotypes of the donor: Common T
cell epitopes and HLA-DR motifs
Variability in HLA molecule defines which type of pep-
tides are bound and presented to T cells. Some rules of
amino acids in key or anchor positions have been for-
mulated and patterns of amino acids demanded are
called motifs (Rammensee et al., 1995). Peptide 27 (LRT-
NNSATIVMPYINSVPMD) from VP2 protein stimulated T
cells most often, as it was recognized by altogether nine
T cell lines (Table 1). It mainly stimulated T cell lines
established from donors carrying HLA-DR1 and/or -DR2
molecules but also two T cell lines established from
donors with HLA-DR4 or HLA-DR9 recognized it. The
overlapping area between peptides 26 and 27 contained
sequence LRTNNSATI and the middle of peptide 27
contained sequence ATIVMPYIN, which both exactly fit
the DR1 motif (actual motif is shown in bold) (Ram-
mensee et al., 1995). Most DR1-positive lines stimulated
by peptide 27 also recognized peptide 26. Peptide 28
was recognized by five T cell lines and three of them
were established from donors with HLA-DR2 molecule
and also recognized peptide 27. No complete DR2 motif
was found either in peptide 27 or 28 but in the overlap-
ping area there is motif MPYINSV with some DR2 anchor
positions (Rammensee et al., 1995).
Both peptides 3 and 9 were recognized by seven T
cell lines and peptide 4 was recognized by six T cell
lines. Peptide 3 (GNSIIHYTNINYYKDAASNS) was rec-
ognized with T cell lines established from donors with
HLA-DR1 and/or -DR2 and/or -DR3 molecule. It con-
tains HLA-DR2 motif IIHYTNI and partially HLA-DR3
motif IIHYTNINY but none of the HLA-DR1 motif (Ram-
mensee et al., 1995). Peptide 4 (NYYKDAASNSANRQD-
FTQDP) was recognized by T cell lines established
from donors sharing HLA-DR1 and/or -DR2 molecule
or HLA-DR9 molecule. It contains HLA-DR1 motif YK-
DAASNSA but none of HLA-DR2 motif (Rammensee et
al., 1995). Peptide 9 (RVRSITLGNSTITTQECANV) did
not contain any clear HLA-DR1 or HLA-DR2 motifs but
it is likely that DR1 epitope was located in the over-
lapping region with peptide 8 because T cell lines
established from donors sharing HLA-DR1 molecule
also had response with peptide 8. In the same manner
T cell lines established from donors with HLA-DR2
molecule also had a sometimes response to peptide
10 and so the HLA-DR2 epitope probably located in the
overlapping region with peptide 10.
Peptide 38 (RNLMEIAEVDSVVPINNLKA) was recog-
nized by five T cell lines, four of them established from
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DR2- and/or DR4-positive donors. It contains two HLA-
DR2 motifs, LMEIAEV and V V PINNL, and one HLA-DR4
motif VVPINNLKA (Rammensee et al., 1995). T cells es-
tablished from donors with HLA-DR4 also recognized the
overlapping peptide 39 sharing the same HLA-DR4 motif
area. The recognized HLA-DR2 epitope located probably
in the middle of the peptide (LMEIAEV) because T cells
established from HLA-DR2-positive donors did not rec-
ognize either peptide 37 or 39.
T cell lines established by different enterovirus
antigens
T cell lines originally raised against one enterovirus
antigen also widely recognized other enterovirus anti-
gens. Three CBV4-specific T cell lines established from
different donors recognized almost all other tested en-
terovirus lysate antigens (CBV3, EV11, CAV16, and PV1)
(Table 2). When specific T cell lines were also estab-
TABLE 1
Positive Peptide Responses (SI  2.0) of 18 CBV4-Specific Human T Cell Lines to 20-aa-long Peptides
with 10 aa Overlaps Covering CBV4 Structural Proteins
Peptide Protein Amino acids Sequence
HLA-DR types of the donors of the responding
T-cell lines
1 VP4 1–20 MGAQVSTQKTGAHETSLSAS DR2,4
3 VP4 21–40 GNSIIHYTNINYYKDAASNS DR1; DR1,8; DR2; DR1,3; DR2,3; DR1,2; DR2,7
4 VP4 31–50 NYYKDAASNSANRQDFTQDP DR1; DR1,8; DR2; DR2,7; DR1,2; DR9
5 VP4 41–60 ANRQDFTQDPSKFTEPVKDV DR2,4; DR1,3; DR1,6
6 VP4 51–70 SKFTEPVKDVMIKSLPALNS DR2,4
7 VP2 61–80 MIKSLPALNSPTVEECGYSD DR2,4
8 VP2 71–90 PTVEECGYSDRVRSITLGNS DR1,3; DR1
9 VP2 81–100 RVRSITLGNSTITTQECANV DR1; DR1,3; DR2; DR2,3; DR2,4; DR2,5; DR1,2
10 VP2 91–110 TITTQECANVVVGYGVWPDY DR2,4; DR2
12 VP2 111–130 LSDEEATAEDQPTQPDVATC DR9
13 VP2 121–140 QPTQPDVATCRFYTLNSVKW DR1,3; DR1,3; DR1
14 VP2 131–150 RFYTLNSVKWEMQSAGWWWK DR1; DR1,3; DR1,3
16 VP2 151–170 FPDALSEMGLFGQNMQYHYL DR1
17 VP2 161–180 FGQNMQYHYLGRSGYTIHVQ DR1
18 VP2 171–190 GRSGYTIHVQCNASKFHQGC DR1
19 VP2 181–200 CNASKFHQGCLLVVCVPEAE DR1; DR1,3
22 VP2 211–230 AYGDLCGGETAKSFEQNAAT DR1,2
23 VP2 221–240 AKSFEQNAATGKTAVQTAVC DR1,3
24 VP2 231–250 GKTAVQTAVCNAGMGVGVGN DR1,3; DR2
26 VP2 251–270 LTIYPHQWINLRTNNSATIV DR1; DR6,7; DR1,3; DR1,3; DR1,6
27 VP2 261–280 LRTNNSATIVMPYINSVPMD DR1; DR2,7; DR2; DR1,3; DR1,6; DR2,4; DR2,7; DR9; DR4
28 VP2 271–290 MPYINSVPMDNMFRHNNFTL DR2,7; DR2,4; DR2,7; DR9; DR4
29 VP2 281–300 NMFRHNNFTLMIIPFAPLDY DR2,7; DR6,7; DR4
33 VP3 321–340 YNGLRLAGHQGLPTMLTPGS DR2,7
36 VP3 351–370 SPSAMPQFDVTPEMNIPGQV DR2,7; DR2,7; DR9
37 VP3 361–380 TPEMNIPGQVRNLMEIAEVD DR4
38 VP3 371–390 RNLMEIAEVDSVVPINNLKA DR2,7; DR2,4; DR2,7; DR9; DR4
39 VP3 381–400 SVVPINNLKANLMTMEAYRV DR2,4; DR4
40 VP3 391–410 NLMTMEAYRVQVRSTDEMGG DR2,4
41 VP3 401–420 QVRSTDEMGGQIFGFPLQPG DR2,7
42 VP3 411–430 QIFGFPLQPGASSVLQRTLL DR2,7
43 VP3 421–440 ASSVLQRTLLGEILNYYTHW DR2,7
44 VP3 431–450 GEILNYYTHWSGSLKLTFVF DR2,4; DR2,7; DR1,2; DR4
45 VP3 441–460 SGSLKLTFVFCGSAMATGKF DR1; DR4
52 VP3 511–530 DDKYTASGFISCWYQTNVIV DR1; DR1,8; DR1,3
55 VP3 541–560 MCFVSACNDFSVRMLRDTQF DR2,4; DR1,2
68 VP1 671–690 LRRKMEMFTYIRCDMELTFV DR4
73 VP1 721–740 VPTSVNDYVWQTSTNPSIFW DR1,4
74 VP1 731–750 QTSTNPSIFWTEGNAPPRMS DR1,4
75 VP1 741–760 TEGNAPPRMSIPFMSIGNAY DR1,6; DR2,3; DR2,4; DR1,4
76 VP1 751–770 IPFMSIGNAYTMFYDGWSNF DR1,4
78 VP1 771–790 SRDGIYGYNSLNNMGTIYAR DR1,4; DR4
79 VP1 781–800 LNNMGTIYARHVNDSSPGGL DR4
80 VP1 791–810 HVNDSSPGGLTSTIRIYFKP DR4
84 VP1 831–850 SVNFDVEAVTAERASLITTG DR9
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lished using CBV4-, CBV3-, EV11-, CAV16, and PV1 anti-
gens, most lines from three donors had positive re-
sponses to CBV4 lysate antigen. Almost the same CBV4
peptides were also recognized without any respect
which enterovirus serotype was used to initiate the line
(Table 3).
T cell epitopes in various structural proteins and
variability between different enteroviruses
Degree of the variability was estimated by comparing
the sequences of other CBV serotypes to the sequence
of CBV4. VP4 is very conserved between CBV serotypes,
as from the 69 aa only four to seven are different (aver-
age of 8% variability). Instead, the variability is high in
VP1 protein as 80–88 of 284 aa are different when com-
pared to CBV4 (average of 29% variability). In VP2 (261
aa) and VP3 (238 aa) the number of different aa were
41–54 (average of 18% variability) and 37–52 aa (average
of 19% variability), respectively (Table 4). Eighteen CBV4-
specific T cell lines recognized one of the six VP4 pep-
tides 19 times, one of the 26 VP2 peptides 50 times, one
of the 24 VP3 peptides 27 times, and one of the 29 VP1
peptides 13 times (Table 4). Percentage of recognized
peptide was calculated with the formula [(number of
recognized peptide)/(number of T cell line  number of
peptide)]  100%. Thus on average 18% of VP4 peptides,
11% of the VP2 peptides, 6% of VP3 peptides but only 2%
of VP1 peptides were recognized when positive re-
sponses with all the 18 CBV4 specific T cell lines were
analyzed (Table 4).
T cell recognition and variability in the peptides
between enteroviruses
The variability in various peptides was compared us-
ing sequences of CBV3, CBV4, EV11, CAV16, and PV1
viruses and two groups of peptides were selected. The
first group contained peptides 1, 3, 4, 5, 6, 7, 8, 9, 10, 13,
16, 17, 18, 19, 26, 27, 34, 44, 45, 46, 48, 49, and 74, which
were highly conserved (over 76% identity, mean 81%
identity). Another group contained peptides 20, 21, 22, 23,
24, 39, 40, 41, 56, 57, 58, 64, 65, 66, 69, 70, 77, 78, 83, 84,
TABLE 2
Three CBV4-Specific T Cell Lines Established from Different
Subjects Recognized Widely also Other Enterovirus Antigens
CBV4-specific
T cell lines
Antigen (SI)
CBV4 CBV3 EV11 CAV16 PV1
Subject 1 5.5 3.6 6.4 1.5 2.3
Subject 2 2.1 3.8 2.5 3.8 3.3
Subject 3 3.7 1.6 2.7 2.1 1.6
Note. The responses are expressed in stimulation index, as defined
under Materials and Methods. Neutralizing antibodies of the subjects:
(1) CBV4, CBV3, E11; (2) CBV4, CBV3, EV11; (3) CBV4,
CBV3, EV11. Neutralizing antibodies against CAV16 or PV1 were not
analyzed, but all subjects had a valid polio vaccination history.
TABLE 3
Five T-Cell Lines Were Established from Three Subjects Using CBV4, CBV3, EV11, CAV16, and PV1 Antigens
Target antigen of
the T cell line
Antigen
Subject 1 Subject 2 Subject 3
CBV4 (SI)
CBV4 peptides with
positive response CBV4 (SI)
CBV4 peptides with
positive response CBV4 (SI)
CBV4 peptides with
positive response
CBV4 5.5 7, 9, 13 2.1 26, 27 3.7 8, 9, 13, 19, 26, 27
CBV3 2.5 6, 7, 9, 10, 11, 12, 14, 56 1.2 — 6.0 8, 9, 13, 14, 16, 19, 27
EV11 4.7 9 1.6 26, 27 8.1 3, 4, 8, 9, 13, 14, 16, 17, 19, 26
CAV16 1.4 — 3.0 26, 27 2.6 —
PV1 1.0 — 1.4 – 6.1 —
Note. Responses to CBV4 antigen are expressed in stimulation index. CBV4 peptides with positive response (SI  2) were shown.
TABLE 4
Number of T Cell Responses to Synthetic Peptides Derived from
Various CBV4 Structural Proteins
CBV4 peptides
(number of the
peptides in each
protein)
Number of
peptides
recognized by
18 T cell lines
Percentage of
recognized
peptides (%)
Degree of
variability
between
CBVs (%)
VP4 peptides
(n  6) 19 18 8
VP2 peptides
(n  26) 50 11 18
VP3 peptides
(n  24) 27 6 19
VP1 peptides
(n  29) 13 2 29
Note. Percentage of recognized peptides was calculated with the
formula [(number of the recognized peptide)/(number of T cell lines 
number of peptide)]  100%. Degree of the variability in various struc-
tural proteins was calculated when sequences of other CBVs were
compared to sequence of CBV4.
221T CELL EPITOPES IN CBV4 STRUCTURAL PROTEINS
and 85, which were less conserved (less than 49% iden-
tity, mean 32% identity). Percentage of recognized pep-
tides was 15% in the group of conserved peptides but
only 3% in the group of peptides with high variability (P 
0.0001, Fisher’s exact test) (Table 5).
Neutralizing antibodies in the donors
Neutralizing antibodies to CBV1, CBV2, CBV3, CBV4,
CBV5, CBV6, EV6, EV9, EV11, and CAV9 were tested from
sera of 19 donors. They all had neutralizing antibodies to
at least one of the tested enterovirus serotypes. Two
donors had antibodies to nine examined serotypes and
one donor had antibodies against only one serotype, but
the average seropositivity was five. Eleven donors had
neutralizing antibodies to CBV4. CBV4-specific T cell
lines have been established from 16 tested donors and
10 of them had neutralizing antibodies against CBV4. The
percentage of CBV4 peptides recognized by 10 T cell
lines, which were established from CBV4-seropositive
donors (VP4 17%, VP2 10%, VP3 4%, and VP1 2%, respec-
tively), was comparable to that of peptides recognized by
all T cell lines (Table 4).
Eight peptides (21, 22, 23, 40, 65, 66, 84, and 85) were
defined specific to CBV4 because they had less than 10
common amino acids with other CB viruses and CAV16,
PV1, and EV11. Ten CBV4-specific T cell lines established
from donors with neutralizing antibodies to CBV4 re-
sponded three times to any of CBV4-specific peptides
(4%), while six CBV4-specific T cell lines established
from donors without CBV4-specific neutralizing antibod-
ies responded once to these peptides (2%). This differ-
ence was not significant by Fisher’s exact test (Table 5).
T cell lines, established from donors with or without
CBV4-specific neutralizing antibodies, did not show any
differences in responses to either less conserved or
highly conserved peptides (Table 5).
DISCUSSION
This is the first study in which the localization of
epitopes recognized by human T cells in enterovirus
structural proteins has been systematically studied. We
generated a panel of CBV4-specific T cell lines from
healthy donors representing various HLA genotypes and
tested their responses to 20-aa-long synthetic peptides
covering the whole sequence of CBV4 structural pro-
teins. The use of CBV4-specific T cell lines ensures that
the detected epitopes are naturally processed epitopes
of CBV4 proteins. Direct stimulation of peripheral blood
lymphocytes by synthetic peptides may produce nonspe-
cific reactivity due to the described wide cross-reactivity
of T cell recognition (Wucherpfennig and Strominger,
1995).
T cell epitopes of all enterovirus structural proteins
have not been previously characterized using this type of
study design. Enteroviral T cell epitopes cross-reactive
between various serotypes have been earlier reported by
using direct stimulation of peripheral blood lymphocytes
with fifteen 9- to 19-aa-long synthetic peptides covering
conserved regions in structural proteins (Cello et al.,
1996). T cell epitopes were localized mainly in the capsid
proteins VP2 and VP3 and to a lesser extent in VP1 but
none in the VP4 protein (Cello et al., 1996). Lack of the
responses in the VP4 protein in this study is not surpris-
ing because it is possible that their two short VP4 pep-
tides (12- to 13-aa-long) did not include any minimal
epitopes. Also few poliovirus epitopes have been de-
scribed near neutralizing antibody epitopes in VP1 of
PV1 and PV3 (Graham et al., 1993; Simons et al., 1993).
In the present study the found epitopes were concen-
trated to the regions which are conserved among differ-
ent enteroviruses, indicating that high cross-reactivity
between enteroviruses might be expected. Only few
epitopes could be mapped to a variable region. Six of the
seven dominant peptide epitopes 3, 4, 9, 26, 27, and 28
were found in the VP4 and VP2 regions, whereas there
was only one dominant peptide epitope in VP3 region
(peptide 38) and none in the VP1 region. All of the 18
tested CBV4-specific T cell lines recognized peptides
covering the sequence of CBV4-VP2 and/or -VP4 pro-
teins, whereas only six T cell lines of 15 recognized some
of the CBV4-VP1 peptides. All six CBV4-specific T cell
lines with positive response to CBV4-VP1 peptide(s) also
had positive response to CBV3-VP1 protein even if the
identity of the VP1 proteins between CBV4 and CBV3
was only 69%. In concordance with that, the sequence of
these VP1 epitopes was also relatively conserved as
compared with rest of VP1 protein. As expected, all lines
responding to CBV4 VP2 and/or VP4 peptides were also
recognizing the in vitro produced CBV4-VP0 protein con-
taining these two polypeptide chains.
After depletion of CD8-positive T cells CBV4-specific
T-cell line recognized all the same peptides as the orig-
TABLE 5
Percentage of Recognized Peptides When All CBV4-Specific T Cell
Lines Were Included (all) or When T Cell Lines from Donors with
(CBV4-ab) or without (CBV4-ab) CBV4-Specific Neutralizing Anti-
bodies Against CBV4 Were Included
Donors
Highly conserved
peptides
(n  23)
Less conserved
peptides
(n  21)
CBV4-specific
peptides
(n  8)
All (n  18) 15%a 3%a 3%
CBV4-ab
(n  10) 13%b 2% 4%
CBV4-ab
(n  6) 14%b 5% 2%
Note. For peptides included, see Results.
a P  0.0001.
b P  ns.
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inal one. So in all likelihood the T cell epitopes found in
our study were mainly mediated by CD4-positive T cells.
The function of CD8-positive T cells, which were involved
in our T cell lines, remains unknown. In our recent work
we found that the T cell epitopes on the CBV4 2C protein
were widely distributed, but HLA-DR identical subjects
recognized highly similar epitopes and we suggested
that HLA-DR genotype of the donors mainly defines the
pattern of the recognized peptide epitopes (Marttila et
al., 2001). The previous studies were instead made with-
out HLA genotype information of the donors (Cello et al.,
1996; Graham et al., 1993). In this study, we also found
that the pattern of recognized peptides was defined by
the HLA II genotype of the donor and that the established
HLA-DR motifs (Rammensee et al., 1995) could to a
certain extent explain the HLA-specific recognition.
We also found that the pattern of recognized peptides
was similar regardless of the CBV4-specific neutralizing
antibodies of the T cell donor and that T cells from
donors with CBV4-specific neutralizing antibodies did
not significantly recognize CBV4 specific peptides more
often. It is obvious that the targets of the T cell immunity
against enteroviruses are very different from the struc-
tures recognized by humoral immunity. Neutralizing an-
tibodies are serotype specific by definition and the main
target of the antibodies is variable VP1 protein, whereas
T cell immunity is highly cross-reactive between different
enterovirus serotypes and the main targets are the con-
served regions mainly in the VP4 and VP2 proteins.
We thus detected an inverse correlation between the
degree of variability in the proteins between enterovi-
ruses and the number of T cell epitopes which were
recognized within them. Epitopes shared by several se-
rotypes are recognized in repeated infections and re-
sponsiveness may thus be enhanced, or alternatively, the
probability of an encounter with these specific epitopes
is higher. The results of previous studies emphasizing
the significance of the highly conserved nonstructural 2C
protein of CBV4 as a target of T cell responsiveness are
also in line with the present observations (Marttila et al.,
2001; Varela-Calvino et al., 2000). On average as much as
17% of 20-aa-long synthetic peptides covering this pro-
tein were stimulating a panel of T cell lines (Marttila et
al., 2001). This figure is very similar to the percentage of
18% found for VP4 peptides in this study.
The mapping of antigenic epitopes is of apparent
importance for the development of subcomponent or
synthetic epitope-based enterovirus vaccines in the fu-
ture. Although neutralizing antibodies are needed for
protection against enterovirus infections, their produc-
tion is dependent on T cell help. Several conserved
regions with high cross-reactivity between different en-
terovirus serotypes mainly in the VP4 and VP2 proteins
are available and might be connected to structures able
to induce neutralizing antibodies. Large variation of the
recognized T cell epitopes between individuals with dif-
ferent HLA-DR genotypes should be taken into account
and peptides recognized by all specificities selected.
The question whether some T cell responses may be
harmful because of the molecular mimicry between viral
and tissue structures and may participate in the patho-
genesis of autoimmune diseases must also be solved
before safe vaccines can be designed.
MATERIALS AND METHODS
Enterovirus lysate antigens
Coxsackievirus B4 (JVB), coxsackievirus B3 (Nancy),
echovirus 11 (Gregory), coxsackievirus A16 (G-10), and
poliovirus 1 (Sabin) were grown in ML-2 LLC cells
(ATCC). Infected cell cultures were harvested when cells
detached freely from the flask surface. The infected cells
and supernatant fluids were frozen and quickly thawed
three times. The suspensions were clarified by centrifu-
gation (8000 rpm, 5 min) and the supernatants were used
as antigens. The antigens were inactivated with beta-
propiolactone. Their protein concentrations were mea-
sured using the Pierce BCA protein assay reagent
(Pierce, Rockford, IL).
CBV-GST proteins
The fusion proteins were prepared as described else-
where (Ha¨rko¨nen et al., 1997). Full-length CBV3 or CBV4
cDNA was used as a template to amplify the genes by
PCR. The VP1 gene of CBV3 and VP0 gene of CBV4 were
cloned into pGEX vector (Pharmacia, Uppsala, Sweden)
and expressed as GST fusion proteins (GST-VP0 or GST-
VP1) in Escherichia coli. GST-VP0 and GST-VP1 were
purified using a glutathione–sepharose column (GST
Gene Fusion System, Pharmacia Biotech, Uppsala, Swe-
den).
Peptides
Eighty-six 20-amino-acid-long synthetic peptides with
10 aa overlaps covered the whole CBV4 structural pro-
teins sequences of the JBV strain (Jenkins et al., 1987).
The peptides were synthesized by F-moc [N-(9-fluorenyl)-
methoxycarbonyl] chemistry on a simultaneous multiple
peptide synthesizer (SMPS 350, Zinsser Analytic, Frank-
furt a/M, Germany). Purity of the peptides was analyzed
by reversed-phase HPLC (Hewlett–Packard 1100 series,
Waldbronn, Germany).
T cell lines
Eighteen laboratory staff members donated blood for
the study. Peripheral blood mononuclear cells (PBMC)
were isolated from heparinized venous blood by Ficoll–
Paque (Uppsala, Sweden) gradient centrifugation. PBMC
(2  106/ml) were incubated with the CBV4 antigen (10
g/ml) in RPMI 1640 medium supplemented with 10%
human AB serum, gentamycin sulphate (10 g/ml),
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HEPES buffer solution 1 M (20 l/ml), and 3% glutamine
(10 l/ml). After 7 days, fresh medium supplemented with
0.5 ng/ml recombinant human IL-2 (R&D Systems Inc.,
Minneapolis, MN) was added every second or third day.
After a total of 14 days from the beginning, the T cells
were restimulated with both CBV4 antigen and irradiated
(30 Gy) autologous antigen presenting cells (2  106
PBMC/ml). T cell lines were restimulated at 7-day inter-
vals; IL-2 was added 2 days after antigen stimulation and
at 2- to 3-day intervals thereafter. All T cell lines had
more than two cycles of stimulation with CBV4 virus
antigen, irradiated autologous APC, and IL-2. The T cell
lines did not respond to control cell lysate or to GST
protein. An average of 93% of cells were CD3 positive
and 42% of them were CD4 positive and 27% CD8 posi-
tive when the phenotype of 10 T cell lines was analyzed
by flow cytometry (Facscan, Becton–Dickinson, Moun-
tain View, CA) using FITC- or phycoerythrin-conjugated
mAb (Coulter, Hialeah, FL) for the CD3, CD4, and CD8 T
cell surface markers, respectively.
Lymphocyte proliferation assay
Triplicate cultures of 5–10  103 T cells per well were
incubated with 2  104 antigen-presenting cells (PBMC)
and antigen in 200 l volumes in 96-well round-bottomed
microtiter plates for 2 days. Tritiated thymidine (2 Ci/ml)
was added 18 h before harvesting the cultures. Incorpo-
rated radioactivity was measured by 1450 Microbeta
Plus liquid scintillation counter (Wallac, Turku, Finland).
Stimulation index (SI) was calculated by dividing the
median of stimulated triplicate culture wells by the me-
dian of the unstimulated wells.
HLA typing
HLA typing of blood donors was done using panels of
commercial antisera (Biotest, Dreieich, Germany) in
standard microlymphocytotoxicity test. B cells for HLA
class II typing were enriched using immunomagnetic
beads (Dynal, Oslo, Norway).
Neutralizing antibodies
Serotype-specific antibodies against coxsackievirus B
serotypes 1 to 6, echovirus serotypes 6, 9, and 11, and
coxsackievirus A serotype 9 were analyzed using stan-
dard plaque neutralization assay. Titers below 4 were
considered negative.
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